Laboratorio di Biotecnologie Applicate all'Ortopedia, IRCCS Istituto Ortopedico Galeazzi, Via Cristina Belgioioso 173, 20157 Milano, Italy.
Dipartimento di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
Int J Mol Sci. 2024 Jan 25;25(3):1461. doi: 10.3390/ijms25031461.
The therapeutic effect of mesenchymal stromal cells (MSCs) has been described for a variety of disorders, including those affecting musculoskeletal tissues. In this context, the literature reports several data about the regenerative effectiveness of MSCs derived from bone marrow, adipose tissue, and an amniotic membrane (BMSCs, ASCs, and hAMSCs, respectively), either when expanded or when acting as clinical-grade biologic pillars of products used at the point of care. To date, there is no evidence about the superiority of one source over the others from a clinical perspective. Therefore, a reliable characterization of the tissue-specific MSC types is mandatory to identify the most effective treatment, especially when tailored to the target disease. Because molecular characterization is a crucial parameter for cell definition, the need for reliable normalizers as housekeeping genes (HKGs) is essential. In this report, the stability levels of five commonly used HKGs (, , , , and ) were sifted into BMSCs, ASCs, and hAMSCs. Adult and fetal/neonatal MSCs showed opposite HKG stability rankings. Moreover, by analyzing MSC types side-by-side, comparison-specific HKGs emerged. The effect of less performant HKG normalization was also demonstrated in genes coding for factors potentially involved in and predicting MSC therapeutic activity for osteoarthritis as a model musculoskeletal disorder, where the choice of the most appropriate normalizer had a higher impact on the donors rather than cell populations when compared side-by-side. In conclusion, this work confirms HKG source-specificity for MSCs and suggests the need for cell-type specific normalizers for cell source or condition-tailored gene expression studies.
间充质基质细胞(MSCs)的治疗效果已在多种疾病中得到描述,包括影响肌肉骨骼组织的疾病。在这种情况下,文献报道了关于骨髓、脂肪组织和羊膜来源的 MSCs(分别为 BMSCs、ASCs 和 hAMSCs)的再生有效性的几个数据,无论是在扩增时还是在作为临床级生物制品的支柱用于护理点时。迄今为止,从临床角度来看,尚无关于一种来源优于另一种来源的证据。因此,必须对组织特异性 MSC 类型进行可靠的表征,以确定最有效的治疗方法,尤其是在针对目标疾病进行定制时。由于分子表征是细胞定义的关键参数,因此需要可靠的内参基因(HKGs)作为正常化因子。在本报告中,五种常用 HKGs(,,,,和)在 BMSCs、ASCs 和 hAMSCs 中的稳定性水平进行了筛选。成体和胎儿/新生儿 MSC 显示出相反的 HKG 稳定性排名。此外,通过并排分析 MSC 类型,出现了特定于比较的 HKG。在以骨关节炎为模型肌肉骨骼疾病的潜在参与和预测 MSC 治疗活性的因子的基因编码中,表现不佳的 HKG 正常化的效果也得到了证明,选择最合适的正常化因子对供体的影响比对并排的细胞群体的影响更大。总之,这项工作证实了 HKG 对 MSC 的来源特异性,并表明需要针对细胞类型特异性的正常化因子进行细胞来源或条件定制的基因表达研究。